Galera Therapeutics, Inc.

OTCPK:GRTX.D Stock Report

Market Cap: US$13.3m

Galera Therapeutics Past Earnings Performance

Past criteria checks 3/6

Galera Therapeutics has been growing earnings at an average annual rate of 45.4%, while the Biotechs industry saw earnings growing at 36.2% annually.

Key information

45.36%

Earnings growth rate

51.32%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity2,967.05%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

No updates

Recent updates

Analysis Article • Feb 15

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 25

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Sep 01

Galera Therapeutics appoints chief medical officer

Biopharmaceutical company Galera Therapeutics (NASDAQ:GRTX) appointed Eugene Kennedy chief medical officer. Kennedy, who has served as chief medical officer at Innovative Cellular Therapeutics, will succeed Jon Holmlund. Holmlund will retire at 2022-end, and in the interim, Kennedy and Holmlund will work together closely to ensure a smooth and successful transition. Source: Press Release
Seeking Alpha • Jun 29

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Galera Therapeutics (NASDAQ:GRTX) stock has lost 7.8% to $1.42 in Wednesday morning trade after announcing phase 1 data for its molecule rucosopasem in combination with stereotactic body radiation therapy to treat patients with non-small cell lung cancer. The results from the early-stage phase of the GRECO-1 trial showed that rucosopasem was safe and well tolerated in a group of seven patients, GRTX said. The results also showed early indications of anti-cancer activity and pulmonary function preservation. GRTX said enrollment is now ongoing in the placebo-controlled phase 2 stage of the trial.
Analysis Article • Jun 15

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 23

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Galera Therapeutics is developing drugs that reduce side effects from anti-cancer radiotherapy and improve the treatment outcome. Clinical trial data have demonstrated statistically significant efficacy for the Avasopasem drug against severe oral mucositis. A pending meeting with the FDA this year could open the door for a new drug application. The stock looks interesting on the selloff.
Analysis Article • Feb 24

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Dec 24

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

In October, GRTX announced that its phase 3 trial failed. In December, GRTX said the trial had actually succeeded. The stock tanked in October, then recovered in December, but not by as much.
Analysis Article • Nov 04

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Aug 05

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Feb 17

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Revenue & Expenses Breakdown

How Galera Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:GRTX.D Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2606450
31 Dec 2506460
30 Sep 250-860
30 Jun 250-1280
31 Mar 250-15102
31 Dec 240-19113
30 Sep 240-20116
30 Jun 240-291312
31 Mar 240-461918
31 Dec 230-592324
30 Sep 230-702629
30 Jun 230-712631
31 Mar 230-642230
31 Dec 220-622031
30 Sep 220-632032
30 Jun 220-692139
31 Mar 220-772148
31 Dec 210-812152
30 Sep 210-842058
30 Jun 210-781855
31 Mar 210-751753
31 Dec 200-741655
30 Sep 200-721454
30 Jun 200-701252
31 Mar 200-651048
31 Dec 190-59842
30 Sep 190-52736
30 Jun 190-43729
31 Mar 190-36623
31 Dec 180-30619

Quality Earnings: GRTX.D has a large one-off gain of $154.5M impacting its last 12 months of financial results to 31st March, 2026.

Growing Profit Margin: GRTX.D became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: GRTX.D has become profitable over the past 5 years, growing earnings by 45.4% per year.

Accelerating Growth: GRTX.D has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: GRTX.D has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: GRTX.D's Return on Equity (2967.1%) is considered outstanding.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/14 00:40
End of Day Share Price 2026/07/14 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galera Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
null nullBTIG
Yigal NochomovitzCitigroup Inc